Table 5
Ocular and systemic adverse events occurring in ⩾1% of either treatment group: number of patients in whom the event occurred at least once
| Latanoprost (n = 351) No (%) | Current dual therapy (n = 115) No (%) | |||
|---|---|---|---|---|
| *Includes accidents, falls, fractures, etc. | ||||
| Ocular adverse event | ||||
| Eye irritation | 19 (5.4) | 7 (6.1) | ||
| Cataract/lens opacity | 10 (2.8) | 5 (4.3) | ||
| Conjunctivitis/blepharitis | 10 (2.8) | 4 (3.5) | ||
| Hyperaemia | 8 (2.3) | 3 (2.6) | ||
| Visual field defect | 7 (2.0) | 10 (8.7) | ||
| Vision decreased/blurred | 6 (1.7) | 4 (3.5) | ||
| Corneal disorder | 4 (1.1) | - | ||
| Conjunctival disorder | 1 (0.3) | 2 (1.7) | ||
| Systemic adverse event | ||||
| Infection, various | 8 (2.3) | 2 (1.7) | ||
| Arthritis/muscle pain | 7 (2.0) | - | ||
| Gastrointestinal symptoms | 6 (1.7) | 3 (2.6) | ||
| Headache | 5 (1.4) | - | ||
| Insomnia | 4 (1.1) | - | ||
| Skin/hair disorder | 3 (0.9) | 3 (2.6) | ||
| Trauma* | 4 (1.1) | 1 (0.9) | ||
| Aggravated hypertension | 3 (0.9) | - | ||
